Puertas B, González-Calle V, Sureda A, Moreno MJ, Oriol A, González E, Rosiñol L, López J, Escalante F, Martínez-Lopez J, Carrillo E, Clavero E, Ríos-Tamayo R, Rey-Bua B, González-Rodríguez AP, Dourdil V, de Arriba F, González S, Pérez-de-Oteyza J, Hernández MT, García-Mateo A, Bargay J, Bladé J, Lahuerta JJ, San Miguel JF, Ocio EM, Mateos M-V. Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup&gt; and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. Haematologica 2023;108(10):2753-2763; https://doi.org/10.3324/haematol.2022.282490.